CN102579492A - Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof - Google Patents
Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof Download PDFInfo
- Publication number
- CN102579492A CN102579492A CN2012100548271A CN201210054827A CN102579492A CN 102579492 A CN102579492 A CN 102579492A CN 2012100548271 A CN2012100548271 A CN 2012100548271A CN 201210054827 A CN201210054827 A CN 201210054827A CN 102579492 A CN102579492 A CN 102579492A
- Authority
- CN
- China
- Prior art keywords
- calf blood
- sodium
- sodium hyaluronate
- blood protein
- removed extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a sodium hyaluronate eyedrop containing deproteinized calf blood extractive. The components comprise deproteinized calf blood extractive, sodium hyaluronate, pH buffering agent, metal chelating agent, osmotic pressure regulation agent and injection water. The preparation method has the following steps: weighing the sodium hyaluronate, adding the injection water to resolve, and obtaining sodium hyaluronate solution after overnight swelling; fetching the deproteinized calf blood extractive, the pH buffering agent, the metal chelating agent and the osmotic pressure regulation agent, adding the injection water to resolve, mixing with the sodium hyaluronate solution after resolving, and agitating uniformly after supplementing the injection water to full dose; filtering and sterilizing after adjusting the pH of the solution, embedding to single dose packaging containers after being qualified by testing, and sealing and obtaining the product. The eyedrop disclosed by the invention is used for curing corneal wounds and xerophthalmia, can promote the corneal cells to incept and utilize the energy, and improves the recovery rate of the corneal wounds. The preparation method of the eyedrop avoids the stimulus to the surface cells of eyes, and prevents the contamination caused by microorganisms in tears and in air during use and storage.
Description
Technical field
The invention belongs to technical field of medicine, be specifically related to a kind of sodium hyaluronate eye drops that contains calf blood protein-removed extraction and preparation method thereof.
Background technology
Xerophthalmia is that clinical ophthalmology is common, with lacrimal secretion reduce, the tear membrane stability reduces and and then to cause the infringement of eye table be the general name of one group of disease of characteristic.Xerophthalmia corneal epithelium point-like comes off; Fluorescent staining is positive; Because the tear film no longer can be born its barrier, immunomodulating and mechanicalness and remove chip and anti-microbial effect; The profuse cornea of sensory nerve directly is exposed to the external world, adds the viscosity chip that is deposited on conjunctival sac and is rolled into the stimulation that thread cornea strips off epithelium, causes patient's symptoms such as dry and astringent, photophobia, foreign body sensation and asthenopia that go out to lose face.The tear film is the barrier of cornea, and conjunctival epithelium is the bedding that the tear film adheres to, and complete epithelial structure helps that the tear film is tensile to be kept; Tear film imperfect can cause the infringement of conjunctival epithelium, and the imperfection of conjunctival epithelium strengthened the difficulty that the tear film adheres to conversely.Therefore, for the patient of xerophthalmia, managing to recover as early as possible the integrity of its corneal epithelium, is an important channel that delays tear film rupture, mitigation symptoms.
Hyaluronic acid sodium is claimed hyaluronate sodium again; It is hyaluronic sodium-salt form; Be the straight chain polymer polysaccharide of glucuronic acid-N-n acetylglucosamine n, be distributed widely in animal and human's body connective tissue cell epimatrix to have extraordinary biocompatibility for disaccharidase unit's composition.Its solution has the viscoelasticity of height, and strand is long more, and viscoelasticity is high more, and viscosity obviously reduces with the increase of shear, even the viscosity of medicinal liquid is very high, eyelid still can be blinked does not have sticky sense freely.In addition eye had lubricated and moisture-keeping function.State Food and Drug Administration issue medical glass acid sodium management of product classification bulletin is announced clear and definite and is used for the hyaluronic acid sodium product that treatment of arthritis, xerophthalmia, skin ulcer etc. have definite pharmacological action.Hyaluronic acid sodium has the characteristic of non-newtonian liquid and fabulous biocompatibility, and sodium hyaluronate eye drops can improve the anterior corneal surface rule property of xerophthalmia patients.Additional sodium hyaluronate eye drops is the most frequently used treatment means of treatment xerophthalmia patients.Sodium hyaluronate eye drops can lubricate the eye surface, improves its irritation, like sensation of dryness and foreign body sensation.In many patients, sodium hyaluronate eye drops also can improve its visual function and alleviate the photophobia phenomenon.Clinically; The xerophthalmia patients that is in a bad way its vision after dripping with sodium hyaluronate eye drops can improve immediately, and sodium hyaluronate eye drops can reduce this type of patient's cornea and indicate regular index (SRI), surperficial asymmetric index (SAI) and improve cornea prediction vision (PVA).Because the uncomfortable frequency of xerophthalmia patients main suit eye maybe be relevant with the scrambling of its anterior corneal surface with the order of severity; In DICON-CT200 corneal topography check system; The SRI and the SAI of the detection xerophthalmia patients anterior corneal surface of reflection anterior corneal surface systematicness can estimate the therapeutic effect of medicine for oculopathy quantitatively; The corneal topography 43.8% that drips the preceding xerophthalmia patients of sodium hyaluronate eye drops is irregular shape, and irregular shape reduces to 29.7% behind the Using Glass acid sodium eye drop.Therefore, we infer the effect that sodium hyaluronate eye drops sodium that this research is used possibly have mucoid appearance.Thereby improve the irregular patient's visual function of anterior corneal surface.
Hyaluronic acid sodium can reduce intraocular pressure behind the glaucoma filtration surgery in treatment, prevents that postoperative from filtering the road cicatrization, keeps functional filtration bubble, make postoperative early, normal intraocular tension control rate at a specified future date increases; And obviously reduced the incidence rate of complication such as postoperative shallow of anterior chamber, thus the serious consequence of avoiding shallow of anterior chamber to cause, and the safety that has improved glaucoma filtration surgery has also improved success rate of operation simultaneously.The existing on the market sodium hyaluronate eye drops product that much contains, such as the beautiful eye drop of love of the towering pharmaceutical manufacturing of Japan, its main component is a hyaluronic acid sodium; Typical concentrations 0.1% is a high molecular polysaccharide, the toughness sterilization aqueous ophthalmic solution of achromaticity and clarification; Has hygroscopicity, Castor Oil eye table.In addition, hyaluronic acid also combines with fibronectin, promotes the connection and the stretching, extension of corneal epithelial cell through the latter's effect, thereby promotes the corneal epithelial cell repair in trauma.Data shows, likes that the damaged healing of beautiful eye drop corneal epithelial has remarkable facilitation, and total effective rate is 92.88%, apparently higher than normal saline 25.0% (P < 0.01).Tangible drug reaction does not appear in the clinical observation.So, like beautiful eye drop regeneration of corneal epithelium, promote the effect that corneal epithelial cell is repaired, and the damage that comes off again that can delay and alleviate corneal epithelium to a certain extent, be a kind of medicine of safer efficacious therapy corneal epithelial defect.
Calf blood protein-removed extraction is a kind of bioactive substance that German scholar professor Jaeger studies invention; It is from six months health of new life and grows the vigorous bovine blood; Process molecular weight less than 6000 Deproteinization blood extract with membrane filtration technique; The organic principle that comprises has materials such as amino acids, low molecular polypeptide, nucleic acid class, oligosaccharide, glycolipid class and organic acid, the component more complicated, but molecular weight is less.Calf blood protein-removed extraction can promote picked-up and the utilization (do not rely on insulin) of cell mitochondrial to glucose and oxygen on cellular level, make the synthetic increase of ATP, and cell ability improves, and activates the plurality of enzymes vigor.Under situation such as low blood oxygen and energy need increase, improve the histiocyte anaerobic condition rapidly, it is synthetic to suppress lactic acid, and microcirculation improvement activates the histiocyte hypertrophy, prolongs the cells survival time, is a kind of efficient cell nutritious element and the promoting growth of cell factor.
Calf blood protein-removed extraction does not contain antigen, safety non-toxic, and as the metabolic medicine of a kind of promotion cellular energy, effect is better clinically, is mainly used in treatment traumatic, struvite and trophism cornea, conjunctive disorder and xerophthalmia etc.At present, the mainstream product that contains the calf blood protein extract has the Solcoseryl Eye-Jel (Solcoseryl) of the plain high pharmaceutical manufacturing of actovegin (Actovegin) and Switzerland of Denmark's Metrizamide pharmaceutical manufacturing.But the report that calf blood protein-removed extraction and hyaluronic acid sodium therapeutic alliance are not arranged so far.
Mostly eye drop on the market is multiple-unit container.Preparation is in case behind the Kaifeng, easily use and the preservation process in by tear and airborne microbial contamination, and then produce safety hidden danger.For prevent ophthalmic preparation behind Kaifeng in the repeated use process by the microorganism secondary pollution, ophthalmic preparation has added antibacterial mostly.Though antibacterial is preventing aspect the microbial contamination certain positive effect is arranged, the existence of antibacterial can produce zest to eye table cell.Antipathogenic composition in the eye drop can directly influence the composition of tear, changes the microenvironment of eyeball surface, and exfoliation of corneal epithelium, damaged, epithelial erosion appear in severe patient, and corneal ulcer can take place, even corneal solution, perforation, blind.The problem that is caused by antibacterial abuse more and more receives publicity, the eye drop that especially often uses for needs, and its potential danger is bigger.Do not work out at present antiseptic as yet to eye table epithelial cell totally nontoxic, because the artificial tears needs to use continuously, thus should avoid adding antibacterial during this type of research xerophthalmia ophthalmic preparation as far as possible, or adopt unit dose package, supply disposable use.
Summary of the invention
Technical problem to be solved by this invention provides and a kind ofly is used to treat corneal injury and xerophthalmia, can promotes keratocyte that the picked-up of energy and utilization, raising corneal injury repair rate contained sodium hyaluronate eye drops of calf blood protein-removed extraction and preparation method thereof.
For realizing above-mentioned purpose, the present invention adopts following technical scheme:
The sodium hyaluronate eye drops that the present invention contains calf blood protein-removed extraction comprises calf blood protein-removed extraction, hyaluronic acid sodium, adjuvant and water for injection; The concentration expressed in percentage by volume of said calf blood protein-removed extraction is 1-50%, and the mass concentration of hyaluronic acid sodium is 0.1-10g/L.
The sodium hyaluronate eye drops that the present invention contains calf blood protein-removed extraction comprises following component:
Calf blood protein-removed extraction 10-500 ml;
Hyaluronic acid sodium 0.1-10 g;
PH buffer agent 1.0-20.0 g;
Metal-chelator 0.05-2.0 g;
Osmotic pressure regulator 1.0-12.0g;
Water for injection 1000ml;
Above-mentioned pH buffer agent, metal-chelator, osmotic pressure regulator are mixed into adjuvant.
Said pH buffer agent is that in EACA, GABA, 5-aminovaleric acid, trometamol, the sodium bicarbonate one or more are composite.
Said metal-chelator is that in disodium edetate, EDTA, aminotriacetic acid, diethylene-triamine pentaacetic acid, the citric acid one or more are composite.
Said osmotic pressure regulator is that in sodium chloride, potassium chloride, boric acid, Borax, sodium sulfate, potassium sulfate, Chile saltpeter, potassium nitrate, sodium acetate, mannitol, glycerol, the glucose one or more are composite.
The present invention contains the method for preparing of the sodium hyaluronate eye drops of calf blood protein-removed extraction, adopts following steps:
(1) takes by weighing 0.1-10 g hyaluronic acid sodium, add the 20%-40% dissolving of water for injection cumulative volume, obtain hyaluronic acid sodium solution after the swelling of spending the night;
(2) get calf blood protein-removed extraction 10-500ml, pH buffer agent 1.0-20.0 g, metal-chelator 0.05-2.0 g, osmotic pressure regulator 1.0-12.0g; Mix with hyaluronic acid sodium solution the 20%-40% dissolving back that adds the water for injection cumulative volume, stirs after additional water for injection to the full dose;
(3) pH to 6.0-7.0 of regulating step (2) gained solution, filtration sterilization is measured in embedding to the unit dose package container of qualified back, seals and obtains product.
Said through the formulation products after step (3) not the capacity specifications of bacteriostatic agent and unit dose package container be 0.3ml.
Good effect of the present invention is following:
The present invention contains in the sodium hyaluronate eye drops of calf blood protein-removed extraction and has added calf blood protein-removed extraction; Itself and hyaluronic acid sodium are used to treat corneal injury, xerophthalmia better as main component, can promote picked-up and the utilization of keratocyte to energy; Improve corneal injury repairing rate; Reduce the occurrence probability of glaucoma filtration post-operative complication simultaneously, intraocular pressure after the stabilization procedure has a extensive future.Eye drop of the present invention prepares and does not add antibacterial in the process, and avoiding eye table cell produced stimulates, and adopts unit dose package, avoided use and the preservation process in by tear and airborne microbial contamination, make eye drop of the present invention more safe and reliable.
The specific embodiment
The good effect of sodium hyaluronate eye drops of the present invention is described through clinical trial below.
(1) experimenter selects:
The patient who selects the corneal epithelial damage is totally 44 examples, equal general diseases such as non-diabetic, hypertension, wherein male 26 examples, women 18 examples, age 18-71 year.The therapist of wherein using the sodium hyaluronate eye drops that the present invention contains calf blood protein-removed extraction totally 22 examples is the A group, wherein male 12 examples, women 10 examples, age 18-65 year, average (46.52 ± 12.14) year old; Therapist 22 examples of using simple glass acid sodium eye drop are the B group, wherein male 14 examples, women 8 examples, age 18-71 year, average (44.98 ± 13.65) year old; Sex composition is than difference not statistically significant (P>0.05) between two groups, and age differences is not statistically significant (P>0.05) also.
(2) Therapeutic Method:
To above A, two groups of patients of B administration respectively; Medication is identical, is 4 times/day, and each 1 splashes in the conjunctival sac; And advise the patient to follow up a case by regular visits in 3 d days in the back of going to a doctor; Carry out record respectively according to symptom and sign formulation standards of grading, estimate the situation of different time points corneal epithelial wound and reparation, 44 examples of on schedule following up a case by regular visits to record are carried out statistical analysis.
(3) standards of grading:
According to patient main suit and the objective sign of using the corneal epithelial wound that slit lamp microscope observation arrives formulate standards of grading.See table 1.
Table 1 corneal epithelium mechanical injuries standards of grading
| Sings and symptoms | 0 minute | 1 minute | 2 minutes | 3 minutes |
| Ophthalmalgia | Do not have | Feel twinge slightly | Obviously twinge but can stand | Obviously twinge and be difficult to stand |
| Photophobia | Do not have | The fear high light | The fear low light level | Be difficult to open eyes |
| Shed tears | Do not have | Slightly shed tears | Opening eyes promptly sheds tears and be difficult to stands | Also shed tears under the closed-eye state |
| The corneal epithelial wound degree | Do not have | Sun Shang ≦ 1/8 quadrant | 1/8 Xiang Xian ≦ Sun Shang ≦ 1/4 quadrant | 1/4 Xiang Xian ≦ Sun Shang ≦ 1/2 quadrant |
(4) statistical procedures:
Each item mark addition of symptom and sign was represented with mean ± standard deviation when the patient was gone to a doctor at every turn.Use the SPSS13.0 statistical software to carry out date processing.Each index and each time point adopt pairing t check to compare respectively, and < 0.05 thinks that difference has statistical significance to P.
(5) result of the test:
Symptom and sign are respectively (7.623 ± 3.113) branch before A, two groups of patient's medications of B, (7.836 ± 2.985) are divided, the two no difference of science of statistics (P>0.05).After the medication 3 days; Two groups of scorings all descend to some extent, are respectively that (2.259 ± 2.143) are divided, (6.062 ± 3.083) are divided, and compare before the medication; Difference all has statistical significance (P < 0.05); And after the medication between two groups of the 3d difference statistical significance (P < 0.05) is also arranged, A group effect obviously is superior to the B group, explain that the effect that the present invention contains the sodium hyaluronate eye drops of calf blood protein-removed extraction is superior to the sour sodium eye drop of simple glass.
Below through specific embodiment the present invention is described further.
Embodiment 1:
The present embodiment eye drop comprises following component:
Calf blood protein-removed extraction 200ml;
Hyaluronic acid sodium 10.0g;
EACA 10.0g;
Disodium edetate 0.05g;
Sodium chloride 10.0g;
Potassium chloride 2.0g;
Water for injection 1000ml.
The method for preparing of present embodiment eye drop adopts following steps:
(1) takes by weighing 10.0 g hyaluronic acid sodiums, add water for injection 400ml dissolving, obtain hyaluronic acid sodium solution after the swelling of spending the night;
(2) get calf blood protein-removed extraction 200ml, EACA 10.0 g, disodium edetate 0.05g, sodium chloride 10.0g, potassium chloride 2.0g; Add water for injection 300ml dissolving back and mix, stir after additional water for injection to the full dose with hyaluronic acid sodium solution;
(3) pH to 6.6 of regulating step (2) gained solution, filtration sterilization, measuring qualified back embedding to capacity specifications is in the unit dose package container of 0.3ml, seals and obtains product.
Embodiment 2:
The present embodiment eye drop comprises following component:
Calf blood protein-removed extraction 10 ml;
Hyaluronic acid sodium 0.1g;
GABA 10.0g;
Trometamol 10.0g;
Aminotriacetic acid 1.0g;
Boric acid 1.0g;
Water for injection 1000ml.
The method for preparing of present embodiment eye drop adopts following steps:
(1) takes by weighing 0.1 g hyaluronic acid sodium, add water for injection 200ml dissolving, obtain hyaluronic acid sodium solution after the swelling of spending the night;
(2) get calf blood protein-removed extraction 10ml, GABA 10.0 g, trometamol 10.0 g, aminotriacetic acid 1.0g, boric acid 1.0g; Add water for injection 200ml dissolving back and mix, stir after additional water for injection to the full dose with hyaluronic acid sodium solution;
(3) pH to 6.0 of regulating step (2) gained solution, filtration sterilization, measuring qualified back embedding to capacity specifications is in the unit dose package container of 0.3ml, seals and obtains product.
Embodiment 3:
The present embodiment eye drop comprises following component:
Calf blood protein-removed extraction 500ml;
Hyaluronic acid sodium 5.0g;
Sodium bicarbonate 1.0g;
Diethylene-triamine pentaacetic acid 1.0g;
Citric acid 1.0g;
Chile saltpeter 8.0g;
Water for injection 1000ml.
The method for preparing of present embodiment eye drop adopts following steps:
(1) takes by weighing 5.0 g hyaluronic acid sodiums, add water for injection 300ml dissolving, obtain hyaluronic acid sodium solution after the swelling of spending the night;
(2) get calf blood protein-removed extraction 500ml, sodium bicarbonate 1.0 g, diethylene-triamine pentaacetic acid 1.0 g, citric acid 1.0g, Chile saltpeter 8.0g; Add water for injection 400ml dissolving back and mix, stir after additional water for injection to the full dose with hyaluronic acid sodium solution;
(3) pH to 7.0 of regulating step (2) gained solution, filtration sterilization, measuring qualified back embedding to capacity specifications is in the unit dose package container of 0.3ml, seals and obtains product.
The above; Be preferable case study on implementation of the present invention; Be not that the present invention is done any restriction, every technical spirit changes any simple modification, change and the equivalent structure that above embodiment did according to the present invention, all still belongs in the protection domain of technical scheme of the present invention.
Claims (7)
1. sodium hyaluronate eye drops that contains calf blood protein-removed extraction; It is characterized in that; Said eye drop comprises calf blood protein-removed extraction, hyaluronic acid sodium, adjuvant and water for injection; The concentration expressed in percentage by volume of said calf blood protein-removed extraction is 1-50%, and the mass concentration of hyaluronic acid sodium is 0.1-10g/L.
2. the sodium hyaluronate eye drops that contains calf blood protein-removed extraction according to claim 1 is characterized in that, it comprises following component:
Calf blood protein-removed extraction 10-500 ml;
Hyaluronic acid sodium 0.1-10 g;
PH buffer agent 1.0-20.0 g;
Metal-chelator 0.05-2.0 g;
Osmotic pressure regulator 1.0-12.0g;
Water for injection 1000ml;
Above-mentioned pH buffer agent, metal-chelator, osmotic pressure regulator are mixed into adjuvant.
3. the sodium hyaluronate eye drops that contains calf blood protein-removed extraction according to claim 2 is characterized in that, said pH buffer agent is that in EACA, GABA, 5-aminovaleric acid, trometamol, the sodium bicarbonate one or more are composite.
4. the sodium hyaluronate eye drops that contains calf blood protein-removed extraction according to claim 2; It is characterized in that said metal-chelator is that in disodium edetate, EDTA, aminotriacetic acid, diethylene-triamine pentaacetic acid, the citric acid one or more are composite.
5. the sodium hyaluronate eye drops that contains calf blood protein-removed extraction according to claim 2; It is characterized in that said osmotic pressure regulator is that in sodium chloride, potassium chloride, boric acid, Borax, sodium sulfate, potassium sulfate, Chile saltpeter, potassium nitrate, sodium acetate, mannitol, glycerol, the glucose one or more are composite.
6. a method for preparing that contains the sodium hyaluronate eye drops of calf blood protein-removed extraction is characterized in that, adopts following steps:
(1) takes by weighing 0.1-10 g hyaluronic acid sodium, add the 20%-40% dissolving of water for injection cumulative volume, obtain hyaluronic acid sodium solution after the swelling of spending the night;
(2) get calf blood protein-removed extraction 10-500ml, pH buffer agent 1.0-20.0 g, metal-chelator 0.05-2.0 g, osmotic pressure regulator 1.0-12.0g; Mix with hyaluronic acid sodium solution the 20%-40% dissolving back that adds the water for injection cumulative volume, stirs after additional water for injection to the full dose;
(3) pH to 6.0-7.0 of regulating step (2) gained solution, filtration sterilization is measured in embedding to the unit dose package container of qualified back, seals and obtains product.
7. the method for preparing that contains the sodium hyaluronate eye drops of calf blood protein-removed extraction according to claim 6 is characterized in that, through the formulation products after step (3) not the capacity specifications of bacteriostatic agent and unit dose package container be 0.3ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100548271A CN102579492A (en) | 2012-03-05 | 2012-03-05 | Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100548271A CN102579492A (en) | 2012-03-05 | 2012-03-05 | Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579492A true CN102579492A (en) | 2012-07-18 |
Family
ID=46469097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100548271A Pending CN102579492A (en) | 2012-03-05 | 2012-03-05 | Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579492A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893742A (en) * | 2014-03-03 | 2014-07-02 | 中山大学中山眼科中心 | Application of vitelline membrane outer layer protein 1 in preparation medicament for treating dry eye disease |
| WO2016083767A3 (en) * | 2014-11-21 | 2016-10-27 | Anant Sharma | Epithelial treatment |
| CN112603926A (en) * | 2020-12-30 | 2021-04-06 | 河南合智医药科技有限公司 | Atropine inosine eye drops for treating myopia and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183302A (en) * | 1996-11-22 | 1998-06-03 | 凌沛学 | Eye drops contg. sodium hyaluronate and preparing method thereof |
| CN101780105A (en) * | 2009-01-20 | 2010-07-21 | 沈阳兴齐制药有限公司 | Eye drop of deproteinized calf blood extractive |
-
2012
- 2012-03-05 CN CN2012100548271A patent/CN102579492A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183302A (en) * | 1996-11-22 | 1998-06-03 | 凌沛学 | Eye drops contg. sodium hyaluronate and preparing method thereof |
| CN101780105A (en) * | 2009-01-20 | 2010-07-21 | 沈阳兴齐制药有限公司 | Eye drop of deproteinized calf blood extractive |
Non-Patent Citations (1)
| Title |
|---|
| 凌沛学等: "壳聚糖及其衍生物的医药研究进展", 《食品与药品》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893742A (en) * | 2014-03-03 | 2014-07-02 | 中山大学中山眼科中心 | Application of vitelline membrane outer layer protein 1 in preparation medicament for treating dry eye disease |
| CN103893742B (en) * | 2014-03-03 | 2016-01-20 | 中山大学中山眼科中心 | Containing the application of the outer albumen 1 of vitellinae membrana in preparation treatment dry eye drug |
| WO2016083767A3 (en) * | 2014-11-21 | 2016-10-27 | Anant Sharma | Epithelial treatment |
| CN112603926A (en) * | 2020-12-30 | 2021-04-06 | 河南合智医药科技有限公司 | Atropine inosine eye drops for treating myopia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20240132A1 (en) | Ophthalmic compositions and methods for treating eyes | |
| JP2611159B2 (en) | Hyaluronic acid pharmacologically active fraction, method for producing the same and pharmaceutical composition | |
| CN107456440A (en) | A kind of low concentration atropic category medicament dropping ocular fluid and preparation method thereof | |
| CN111991415B (en) | Eye care composition and preparation method and application thereof | |
| US20060110459A1 (en) | Triple natural polymer viscoelastic composition | |
| CN108135926A (en) | High resiliency hyaluronic acid compositions and its application method | |
| CN107921056A (en) | Include the ophthalmic preparation of low and high molecular weight hyaluronic acid collaboration compound | |
| CN104984326A (en) | Recombinant human basic fibroblast growth factor gel without bacteriostatic agent and preparation method thereof | |
| CN111803441A (en) | Sodium hyaluronate eye drops containing 0.01% atropine and preparation method thereof | |
| CN110496215A (en) | A kind of aqueous ophthalmic solution and preparation method thereof for treating presbyopia | |
| CN100381169C (en) | Composite collagen eye drops | |
| CN102579492A (en) | Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof | |
| CN102210856B (en) | Collagen eye drops and preparation method thereof | |
| CN108697635A (en) | Ophthalmic composition for treating eye disease related with kerato-conjunctival surface modification | |
| CN102188695B (en) | Ophthalmic gel composition | |
| CN101543509B (en) | Ophthalmic gel containing chondroitin sulfate and method for preparing same | |
| CN101648006A (en) | Medicinal composition for treating glaucoma and application thereof | |
| CN102008488A (en) | Triamcinolone acetonide ophthalmic preparation and preparation method thereof | |
| CN103006706B (en) | Amniotic membrane liposome for ocular surface reconstruction and preparation method and application thereof | |
| CN105214071A (en) | A kind of size variance eye drop and preparation method thereof | |
| CN102178936B (en) | Methods for preparing collagen oleostock and moistening eyedrops | |
| CN105749360B (en) | A kind of composition and the preparation method and application thereof for protecting cornea | |
| CN104546692B (en) | BFGF bovine basic fibroblast growth factor gel for eye use | |
| CN112891326A (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
| CN100362991C (en) | Medicine composition for ophthalmology department |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120718 |